ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    NCT03114657
Previous Study | Return to List | Next Study

A Study of Crenezumab Versus Placebo to Evaluate the Efficacy and Safety in Participants With Prodromal to Mild Alzheimer's Disease (AD) (CREAD 2)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03114657
Recruitment Status : Recruiting
First Posted : April 14, 2017
Last Update Posted : March 20, 2018
Sponsor:
Information provided by (Responsible Party):
Hoffmann-La Roche

March 28, 2017
April 14, 2017
March 20, 2018
March 29, 2017
October 28, 2021   (Final data collection date for primary outcome measure)
Change from Baseline to Week 105 in Clinical Dementia Rating-Sum of Boxes (CDR-SB) Scale Score [ Time Frame: Baseline, Week 105 ]
Same as current
Complete list of historical versions of study NCT03114657 on ClinicalTrials.gov Archive Site
  • Change from Baseline to Week 105 in Alzheimer's Disease Assessment Scale-Cognition 13 (ADAS-Cog-13) Subscale Score [ Time Frame: Baseline, Week 105 ]
  • Time to Clinically Evident Decline [ Time Frame: Baseline up to Week 105 ]
    Clinically evident decline is defined by fulfilment of both of the following criteria: (1) a confirmed decline of greater than or equal to (>=) 2 points on the Mini Mental State Examination (MMSE) scale score; and (2) loss of >=1 point(s) on one or more basic Activity of Daily Living (ADL) subscale(s) score, or loss of >=2 points on one or more Instrumental Activity of Daily Living (iADL) scores. Time to clinically evident decline will be reported.
  • Change from Baseline to Week 105 in Clinical Dementia Rating-Global Score (CDR-GS) [ Time Frame: Baseline, Week 105 ]
  • Change from Baseline to Week 105 in MMSE Scale Score [ Time Frame: Baseline, Week 105 ]
  • Change from Baseline to Week 105 in Alzheimer's Disease Assessment Scale-Cognition 12 (ADAS-Cog-12) Subscale Score [ Time Frame: Baseline, Week 105 ]
  • Time to an Increase of >=4 Points from Baseline at any Time Before or on Week 105 in the ADAS-Cog-13 Subscale Score [ Time Frame: Baseline up to Week 105 ]
  • Change from Baseline to Week 105 in Alzheimer's Disease Cooperative Study−Activities of Daily Living Inventory Instrumental Subscale (ADCS-iADL) Score [ Time Frame: Baseline, Week 105 ]
  • Change from Baseline to Week 105 in Alzheimer's Disease Cooperative Study−Activities of Daily Living Inventory (ADCS-ADL) Total Score [ Time Frame: Baseline, Week 105 ]
  • Change from Baseline to Week 105 in Dependence Level Assessed from the ADCS-ADL Score [ Time Frame: Baseline, Week 105 ]
  • Change from Baseline to Week 105 in Functional Activities Questionnaire (FAQ) Total Score [ Time Frame: Baseline, Week 105 ]
  • Change from Baseline to Week 105 in Neuropsychiatric Inventory Questionnaire (NPI-Q) Score [ Time Frame: Baseline, Week 105 ]
  • Change from Baseline to Week 105 in the Quality of Life-Alzheimer's Disease (QoL-AD) Scale Score [ Time Frame: Baseline, Week 105 ]
  • Change from Baseline to Week 105 in the Zarit Caregiver Interview for Alzheimer's Disease (ZCI-AD) Scale Score [ Time Frame: Baseline, Week 105 ]
  • Change from Baseline to Week 105 in European Quality of Life-5 Dimensions (EQ-5D) Questionnaire Domain Scores [ Time Frame: Baseline, Week 105 ]
  • Percentage of Participants with Adverse Event (AEs) and Serious Adverse Event (SAEs) [ Time Frame: Baseline up to Week 105 ]
  • Percentage of Participants with Anti-Crenezumab Antibodies [ Time Frame: Baseline up to Week 105 ]
  • Serum Concentration of Crenezumab [ Time Frame: Pre-infusion (0 hour), 60-90 minutes post-infusion on Day 1 Week 1 and on Week 25; Weeks 5, 13, 37, 53, and 100 (infusion length = as per the Pharmacy Manual) ]
  • Plasma Amyloid Beta (Abeta) Concentrations [ Time Frame: Screening (Weeks -8 to -1) ; Day 1 Week 1; Weeks 5, 25, 53, and 100 ]
  • Change from Baseline to Week 105 in Brain Volume as Determined by Magnetic Resonance Imaging (MRI) [ Time Frame: Baseline, Week 105 ]
Same as current
Not Provided
Not Provided
 
A Study of Crenezumab Versus Placebo to Evaluate the Efficacy and Safety in Participants With Prodromal to Mild Alzheimer's Disease (AD)
A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy and Safety Study of Crenezumab in Patients With Prodromal to Mild Alzheimer's Disease
This randomized, double-blind, placebo-controlled, parallel-group study will evaluate the efficacy and safety of crenezumab versus placebo in participants with prodromal to mild AD. Participants will be randomized 1:1 to receive either intravenous (IV) infusion of crenezumab or placebo every 4 weeks (q4w) for 100 weeks. The primary efficacy assessment will be performed at 105 weeks. The participants who do not enter open-label extension will enter for a long term follow-up period for up to 52 weeks after the last crenezumab dose (Week 153).
Not Provided
Interventional
Phase 3
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Alzheimer's Disease
  • Drug: Crenezumab
    Crenezumab will be administered as IV infusion q4w for 100 weeks.
  • Drug: Placebo
    Placebo will be administered as IV infusion q4w for 100 weeks.
  • Experimental: Crenezumab
    Participants will receive IV infusion of crenezumab q4w for 100 weeks.
    Intervention: Drug: Crenezumab
  • Placebo Comparator: Placebo
    Participants will receive IV infusion of placebo q4w for 100 weeks.
    Intervention: Drug: Placebo
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
750
Same as current
October 28, 2022
October 28, 2021   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Weight between 40 and 120 kilograms (kg), inclusive
  • Availability of a person (referred to as the "caregiver") who in the investigator's judgment : (a) Has frequent and sufficient contact with the participant to be able to provide accurate information regarding the participant's cognitive and functional abilities, agrees to provide information at clinic visits (which require partner input for scale completion), signs the necessary consent form, and has sufficient cognitive capacity to accurately report upon the participant's behavior and cognitive and functional abilities; (b) Is in sufficiently good general health to have a high likelihood of maintaining the same level of interaction with the participant and participation in study procedures throughout the study duration
  • Fluency in the language of the tests used at the study site
  • Adequate visual and auditory acuity, in the investigator's judgment, sufficient to perform the neuropsychological testing (eye glasses and hearing aids are permitted)
  • Evidence of the AD pathological process, by a positive amyloid assessment either on cerebrospinal fluid (CSF) amyloid beta 1-42 levels as measured on the Elecsys beta-amyloid (1-42) test system or amyloid positron emission tomography (PET) scan by qualitative read by the core/central PET laboratory
  • Demonstrated abnormal memory function at early screening (up to 4 weeks before screening begins) or at screening
  • Evidence of retrospective decline confirmed by a diagnosis verification form
  • Mild symptomatology, as defined by a screening MMSE score of >=22 points and CDR-GS of 0.5 or 1.0
  • Meets National Institute on Aging/Alzheimer's Association (NIAAA) core clinical criteria for probable AD dementia or prodromal AD (consistent with the NIAAA diagnostic criteria and guidelines for mild cognitive impairment [MCI])
  • If receiving symptomatic AD medications, the dosing regimen must have been stable for 3 months prior to screening
  • Participant must have completed at least 6 years of formal education after the age of 5 years
  • For enrollment into the China Extension Phase, participants must have residence in the People's Republic of China

Exclusion Criteria:

  • Any evidence of a condition other than AD that may affect cognition, including but not limited to, frontotemporal dementia, dementia with Lewy bodies, vascular dementia, Parkinson's disease, corticobasal degeneration, Creutzfeldt-Jakob disease, progressive supranuclear palsy, frontotemporal degeneration, Huntington's disease, normal pressure hydrocephalus, seizure disorder, or hypoxia
  • History of schizophrenia, schizoaffective disorder, major depression, or bipolar disorder
  • At risk of suicide in the opinion of the investigator
  • Presence of significant cerebral vascular pathology as assessed by MRI central reader
  • Unstable or clinically significant cardiovascular, kidney or liver disease
  • Uncontrolled hypertension
  • Screening hemoglobin A1c (HbA1C) greater than (>) 8 percent (%)
  • Poor peripheral venous access
  • History of cancer except if considered to be cured or If not being actively treated with anti-cancer therapy or radiotherapy
  • Known history of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric, human, or humanized antibodies or fusion proteins
Sexes Eligible for Study: All
50 Years to 85 Years   (Adult, Senior)
No
Contact: Reference Study ID Number: BN29553 www.roche.com/about_roche/ roche_worldwide.htm 888-662-6728 (U.S. and Canada) global-roche-genentech-trials@gene.com
Argentina,   Australia,   Belgium,   Brazil,   Canada,   China,   Denmark,   Estonia,   France,   Germany,   Greece,   Guatemala,   Hungary,   Israel,   Italy,   Japan,   Korea, Republic of,   Mexico,   Norway,   Peru,   Poland,   Portugal,   Russian Federation,   Serbia,   South Africa,   Spain,   Sweden,   Taiwan,   Turkey,   United Kingdom,   United States
 
 
NCT03114657
BN29553
2016-003288-20 ( EudraCT Number )
Yes
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Not Provided
Hoffmann-La Roche
Hoffmann-La Roche
Not Provided
Study Director: Clinical Trials Hoffmann-La Roche
Hoffmann-La Roche
March 2018

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP